NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYTK shares have increased by 68.2% and is now trading at $20.24. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company earned $3.83 million during the quarter, compared to the consensus estimate of $4.92 million. Cytokinetics had a negative net margin of 592.61% and a negative return on equity of 10,351.99%. View Cytokinetics' earnings history.

7 equities research analysts have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $35.00. On average, they anticipate Cytokinetics' share price to reach $26.43 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price. View analysts' price targets for Cytokinetics.

News coverage about CYTK stock has been trending somewhat positive recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutCytokinetics.

Cytokinetics saw a decline in short interest in May. As of May 15th, there was short interest totaling 7,800,000 shares, a decline of 8.6% from the April 30th total of 8,530,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is currently 7.7 days. Currently, 14.4% of the company's stock are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Mirati Therapeutics (MRTX), PPD (SDGR), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.35%), Wasatch Advisors Inc. (5.05%), State Street Corp (4.52%), Foresite Capital Management IV LLC (3.66%), Two Sigma Advisers LP (1.13%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Federated Hermes Inc., Two Sigma Investments LP, Pinnacle Associates Ltd., UBS Group AG, Arizona State Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Burrage Capital Management LLC, Atom Investors LP, JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Two Sigma Advisers LP, State Street Corp, and Assenagon Asset Management S.A.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $20.24.

Cytokinetics has a market capitalization of $1.20 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]